Lifeward / ReWalk Robotics

Market context

Lifeward is a small but direct public-market exoskeleton name, with robotics exposure centered on assistive mobility and rehabilitation rather than industrial automation.

Facts

• Website: https://golifeward.com
• HQ: Marlborough, Massachusetts, US
• Founded: 2001
• Ticker: LFWD / NASDAQ
• Segment: Healthcare

Lifeward / ReWalk Robotics role in healthcare robotics

Lifeward, formerly ReWalk Robotics, develops wearable robotic exoskeletons and rehabilitation technologies for people with mobility impairments. Lifeward is a small but direct public-market exoskeleton name, with robotics exposure centered on assistive mobility and rehabilitation rather than industrial automation.

• Target environment: Hospitals, surgical centers, rehabilitation settings, pharmacy operations, care providers and medical-device workflows.
• Deployment model: Healthcare robotics model built around devices, enabling technology, procedure support, care workflows or clinical automation.
• Customer context: Medical-device companies, hospitals, surgeons, care providers, rehabilitation teams, pharmacy operators and healthcare buyers.
• Workflow context: Procedure support, rehabilitation, care delivery, pharmacy automation, hospital logistics, clinical data capture and device-assisted workflows.
• Commercial maturity: Published company profile with public sources supporting its robotics-adjacent role; deployment depth varies by product line and customer evidence.
• Market position: Healthcare robotics and medical-automation participant with relevance to procedure, care or device workflows.
• Adoption constraints: Adoption depends on clinical validation, safety, workflow integration, regulatory clearance, purchasing cycles and service support.
• Adjacent context: Surgical robotics, rehabilitation robots, hospital automation, pharmacy automation, clinical devices and assistive technology.
• Source confidence: medium

Events

• 2025-04-15 - Product Launch - Lifeward launches ReWalk 7 exoskeleton sales in the U.S. - Lifeward launched U.S. sales of the ReWalk 7 personal exoskeleton. The launch followed FDA clearance in March 2025. The product is used to support standing and walking for individuals with spinal cord injury.
• 2025-03-13 - Regulatory - Lifeward receives FDA clearance for ReWalk 7 exoskeleton - Lifeward received 510(k) FDA clearance for the ReWalk 7 personal exoskeleton. The seventh-generation ReWalk device is designed for individuals with spinal cord injury. The clearance followed prior FDA clearance for ReWalk stair and curb functionality and CMS…

Team

• Mark Grant - President and Chief Executive Officer - His role covers Lifeward's ReWalk exoskeleton, AlterG anti-gravity systems and rehabilitation technology portfolio.